Introduction
============

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and usually lethal disorder with an unknown etiology, a median survival time of 3--5 years and a mortality rate exceeding those of numerous cancer types ([@b1-ijmm-42-06-3256],[@b2-ijmm-42-06-3256]). Current pathogenetic theories suggest that IPF is a result of an aberrant wound healing response and characterized by injured alveolar epithelium, formation of fibroblast/myofibroblast foci and accumulation of extracellular matrix (ECM) ([@b3-ijmm-42-06-3256]). Despite the marked increase in research efforts, the exact mechanisms involved in the initiation, maintenance and progression of fibrosis remain largely elusive ([@b4-ijmm-42-06-3256]). In recent years, RNA-based regulation, including that involving micro (mi)RNA, long non-coding (nc)RNA or circular (circ)RNA, has been identified in fibrotic disease ([@b5-ijmm-42-06-3256]--[@b7-ijmm-42-06-3256]).

circRNA represents a novel class of endogenous ncRNA, which is observed in a wide variety of organisms ([@b8-ijmm-42-06-3256],[@b9-ijmm-42-06-3256]). Unlike linear RNA, circRNA demonstrates unusual stability due to its unique covalent loop structure with neither 5′ to 3′ polarity nor a polyadenylated tail ([@b10-ijmm-42-06-3256]). With the rapid development of high-throughput sequencing technology, circRNA has been identified to be ubiquitously expressed in various tissues and cells types ([@b11-ijmm-42-06-3256]). Its biogenesis is influenced by cis elements and transfactors, including Alu repeats, reverse complementary matches and RNA-binding protein ([@b12-ijmm-42-06-3256]). Furthermore, tissue, cell type or developmental stage-specific expression patterns imply that circRNA has important biological functions ([@b13-ijmm-42-06-3256],[@b14-ijmm-42-06-3256]). Emerging evidence demonstrates that circRNAs serve as gene regulators in mammals, particularly through functioning as miRNA sponges or mRNA translation templates, facilitating transcription of their host genes by directly associating with RNA polymerase II or forming platforms for protein interactions ([@b15-ijmm-42-06-3256],[@b16-ijmm-42-06-3256]). circRNAs have crucial roles in cell homeostasis and are closely correlated with the clinical and pathological features of various human diseases, including atherosclerosis, neurological disorders, fibrosis and cancer; thus, circRNAs have potential as novel clinical diagnostic and prognostic biomarkers ([@b17-ijmm-42-06-3256],[@b18-ijmm-42-06-3256]). However, neither the formation mechanism nor the cellular function of circRNA has been completely understood in IPF. In the present study, the dysregulated circRNAs in IPF were identified through microarrays and the potential circRNA-associated competing endogenous RNA (ceRNA) network was constructed with the aim to provide novel biomarkers for IPF diagnosis and pathogenesis.

Materials and methods
=====================

Patients and clinical samples
-----------------------------

Patients admitted to the Affiliated Hospital of Binzhou Medical University (Binzhou, China) who were diagnosed with IPF between October 2015 and June 2017 (n=10) through combined clinical, radiological and pathological examination based on the American Thoracic Society/European Respiratory Society consensus criteria ([@b19-ijmm-42-06-3256]) were included in the present study. Normal controls from healthy volunteers were matched corresponding to the IPF patients' sex and age. The healthy non-smoking volunteers were recruited from individuals undergoing a physical examination at the hospital over the same time period. Individuals with respiratory and rheumatic immune diseases were excluded from the study. Fresh peripheral blood samples were collected in EDTA-containing tubes and then centrifuged (1,000 × g for 10 min at room temperature) to isolate the plasma.

RNA extraction and characterization
-----------------------------------

The total RNA of each sample was isolated using TRIzol LS reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's instructions. The RNA quantity and quality were determined using a NanoDrop ND-1000 instrument (Thermo Fisher Scientific, Inc.). A 260/280 nm absorbance ratio between 1.8 and 2.1, or a 260/230 nm absorbance ratio of \>1.8 were acceptable. RNA integrity and genomic DNA contamination were assessed by standard denaturing agarose gel electrophoresis after RNA extraction and prior to sample labelling. DNA contamination was ruled out by the absence of a high molecular-weight smear or band migration above the 28S ribosomal RNA band. RNA integrity was confirmed by the absence of RNA degradation, which was reflected by smearing of ribosomal RNA bands.

Microarray hybridization
------------------------

Arraystar Inc. (Rockville, MD, USA) developed the world's first commercial circRNA chip for systematically analysing the expression of circRNA in different physiological and pathological conditions. The Arraystar Human circRNA Array (8×15 K; Arraystar Inc.) analysis was performed by Kangchen Corp. (Shanghai, China) in 3 pairs of IPF samples and normal control samples. In brief, isolated total RNA was treated with RNase R (Epicenter, Madison, WI, USA) to remove linear RNA. Subsequently, the samples were amplified and transcribed into fluorescent complementary (c)RNA by utilizing a random primer method according to the Arraystar Super RNA Labeling protocol. Subsequently, the labelled cRNA was purified using an RNeasy Mini Kit (Qiagen, Hilden, Germany). The concentration and specific activity of the labelled cRNA (pmol Cy3/*µ*g cRNA) was measured using a NanoDrop ND-1000. A total of 1 *µ*g of each labelled cRNA was then fragmented by adding 5 *µ*l of 10X blocking agent and 1 *µ*l of 25X fragmentation buffer. The mixture was then heated at 60°C for 30 min, and 25 *µ*l 2X hybridization buffer was then added to dilute the labelled cRNA. Subsequently, 50 *µ*l of the hybridization solution was dispensed into the gasket slide and assembled onto the Arraystar circRNA expression microarray slide. The slides were incubated for 17 h at 65°C in an Agilent hybridization oven (Agilent Technologies, Inc., Santa Clara, CA, USA). The slides were washed and the hybridized arrays were scanned using an Agilent G2505C scanner (Agilent Technologies, Inc.). The scanned images were imported into the Agilent feature extraction software (version 11.0.1.1) to extract raw data (Agilent Technologies, Inc.).

Microarray data analysis
------------------------

Quantile normalization of raw data and the subsequent data processing were performed using the R limma package (bioconductor. org/packages/release/bioc/html/limma.html). After quantile normalization of raw data, low-intensity filtering was performed and circRNA with a minimum of 1 out of 6 samples with flags in 'present' or 'marginal' ('all target values') were retained for further analyses. In the comparison of the two groups, namely disease vs. normal controls, the 'fold change' (the ratio of group average values) among groups was computed for each circRNA. Statistical significance of the difference was estimated via a Student's t-test. circRNA with an absolute value of the fold change ≥1.5 and P-values of ≤0.05 were considered to indicate significantly different expression. The final outputs were filtered and the differentially expressed circRNA was ranked based on fold change and P-value, among others, by using the 'Data/Sort' and 'Filter' functions of Microsoft Excel2013 (Microsoft Corp., Redmond, WA, USA). The dataset was deposited in the Gene Expression Omnibus database (<https://www.ncbi.nlm.nih.gov/geo/>) with the accession no. GSE102660.

Reverse transcription (RT)
--------------------------

cDNA for circRNA and mRNA was generated using the Super Script™ III First-Strand Synthesis System (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's protocol. In brief, 3 *µ*g total RNA, 1 *µ*l random primer (N9), 4 *µ*l 5X first-strand buffer, 1.6 *µ*l nucleotide mix, 0.3 *µ*l RNase inhibitor, 1 *µ*l dithiothreitol and 0.2 *µ*l Super Script™ III reverse transcriptase were added to the system, which was then incubated at 50°C for 1 h. The RT reaction and no-template control were performed simultaneously. RT of miRNAs was performed using the Bulge-Loop miRNA primer set according to the manufacturer's protocol (RT miR-324-5p primer, cat. no. ssD809230302; RT miR-630 primer, cat. no. ssD809230591; Guangzhou RiboBio Co., Ltd. (Guangzhou, China).

Quantitative polymerase chain reaction (qPCR)
---------------------------------------------

The expression levels of circRNA and miRNA were evaluated via qPCR using 2X PCR master mix (Arraystar Inc.) and SYBR Green Master Mix (Roche Diagnostics, Basel, Switzerland), respectively, according to the manufacturer's protocol. PCR for circRNA was performed in a 10-*µ*l reaction volume, including 2 *µ*l cDNA, 5 *µ*l 2X Master Mix, 0.5 *µ*l forward primer (10 *µ*M), 0.5 *µ*l reverse primer (10 *µ*M) and 2 *µ*l double-distilled water. The reaction was set at 95°C for 10 min for pre-denaturation, followed by 40 cycles of 95°C for 10 sec and 60°C for 60 sec. GAPDH was used for template normalization of circRNA ([@b20-ijmm-42-06-3256]). PCR for miR-324-5p and miR-630 entailed initiation at 95°C for 20 sec, followed by 30 cycles at 95°C for 10 sec, 60°C for 20 sec and 72°C for 10 sec. PCR and analyses were performed with a ViiA7 Real-time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The *C.*elegans miRNA 39-3p was used as a normalization control. The specific primers for miRNA were purchased from Guangzhou RiboBio Co., Ltd. and their catalogue numbers were as follows: miR-324-5p forward, cat. no. ssD809230994; miR-630 forward, cat. no. ssD090525005; miR-324-5p and miR-630 reverse, cat. no. ssD089261711. Samples for target and reference gene amplification were prepared in triplicate. The gene expression levels were calculated using the ΔCt method ([@b20-ijmm-42-06-3256]). Divergent primers for circRNA were designed to amplify the circRNA-specific back-splice junctions and had the following sequences: hsa_circRNA_100906 forward, 5′-CTGGACAAGGCCACATAGAGT-3′ and reverse, 5′-CAGAGCAGCCAATGAAGACAC-3′; hsa_circRNA_102100 forward, 5′-TCTATTAGGGCATGAGTTTGTCTT-3′ and reverse, 5′-TCCTTGGTTGTGGAGCTGTC-3′; hsa_circRNA_102348 forward, 5′-CCTTTCAGCCCTCCATACTTACT-3′ and reverse, 5′-CCATATTCTTATCAGGCAATCTTGT-3′; hsa_circRNA_101225 forward, 5′-GCACCTGACAGCATCTATTACC-3′ and reverse, 5′-GACAGTAGAAACGCAGTAAGCAA-3′; hsa_circRNA_104780 forward, 5′-ACAGATACCACCGCCGAACT-3′ and reverse, 5′-TCTAGCTCCTTGGCAGGGAT-3′; hsa_circRNA_101242 forward, 5′-GATGCTGCTCAAATGAGAAATG-3′ and reverse, 5′-GCAGGAGAAGTATGTGGAGTAATC-3′. GAPDH forward, 5′-GGGAAACTGTGGCGTGAT-3′ and reverse, 5′-GAGTGGGTGTCGCTGTTGA-3.′

Detection of putative miRNA seed matches
----------------------------------------

The miRNA response elements on circRNA and mRNA were scanned using miRNA target prediction software (version 1.0; Arraystar Inc.) based on miRanda and Target Scan. The differentially expressed circRNA within all comparisons was annotated in detail using the circRNA/miRNA interaction information. mRNA targets were obtained according to the target scores, which were calculated using the formula (\|TargetScan context + score\|+\|probabilities of conserved targeting\|)/2.

Dual-luciferase reporter assay
------------------------------

Luciferase reporter assays were used to detect direct binding between circRNA and miRNAs. pMIR-REPORT Luciferase vector containing firefly luciferase gene (Obio Technology (Shanghai) Corp., Ltd. (Shanghai, China)) and pRL-cytomegalovirus *Renilla* luciferase reporter vector (Promega Corp., Madison, WI, USA) were applied in this experiment. The full length of the respective circRNA was obtained by gene synthesis ([@b21-ijmm-42-06-3256]). The synthesized circRNA was verified and inserted ([@b21-ijmm-42-06-3256]) into the pMIR-REPORT Luciferase vector by Obio Technology.

The mutant sequence was amplified from the wild-type using PCR and mutations in the target site was developed using primers. The mutant sequence was validated by sequencing following plasmid construction. The primer sequences used were as follows: has_circRNA_100906-F1, 5′-ATAGGCCGGCATAGACGCGTTGTCTTCATTGGCTGCTCTG-3′; hsa_circRNA_100906-R1,5′-AAGGAGCCGTCGTACGGTCATCCTGGGCTGTCAGATTTG -3′; hsa_circRNA \_100906- F2,5′-TGACCGTACGACGGCTCCTTTACATCTTGCTGCAACTCATG-3′; hsa_circRNA_100906-R 2,5′-TTCTTACCGTCGTACAAATCACCCTTAAAGGCAGCCACATG-3′; hsa_circRNA_100906-F3,5′-GATTTGTACGACGGTAAGAAATTAGTGGAAGATGGAGTAATC-3′; hsa_circRNA_100906-R3,5′AAAGATCCTTTATTAAGCTTCTCTTTGCCACATCACTGGG-3′; hsa_circRNA_102348-F1, 5′-ATAGGCCGGCATAGACGCGTTTTCAGAAAGTGCTTTCTCTC-3′; hsa_circRNA_102348-R1, 5′-GTTAACCCGTCGTAGTTTCCAAAGGTGCAACGCTCCGTGG-3′; hsa_circRNA_102348-F2, 5′-GGAAACTACGACGGGTTAACCCAAGAGAGTGGACTCCAGAGA-3′; and hsa_circRNA_102348-R2, 5′-AAAGATCCTTTATTAAGCTTAGTTTTTGAACTTCAGGCCACAACCGTCGTAGCAGAAGATGATCCT-3′. Mutations were introduced to verify the predicted miRNA binding sites. miRNA mimics and their negative control were obtained from Gene Pharma (Shanghai, China); they were co-transfected into 293T cells (Cell Bank of the Chinese Academy of Sciences, Shanghai, China) with the pMIR-REPORT Luciferase vector with or without the full-length sequence of circRNA by using Lipofectamine-2000^®^ (Invitrogen; Thermo Fisher Scientific, Inc.). After transfection for 48 h, luciferase activities were detected with the dual-Luciferase Reporter Assay System (Promega Corp.) according to the manufacturer's protocols. Relative light units were determined with a SpectramaxM2 (Molecular Devices, LLC, Sunnyvale, CA, USA). Firefly luciferase values were normalized to the corresponding Renilla luciferase values.

Statistical analysis
--------------------

Values are expressed as the mean ± standard deviation. Student's t-test was used for comparison between two groups. Statistically significant differences from multiple groups were determined using one-way analysis of variance with the Student-Newman-Keuls post hoc test. All analyses were performed using SPSS Statistics software package (version 11.0 for Windows; SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Identification of differentially expressed circRNA profiles during IPF development
----------------------------------------------------------------------------------

IPF is clinically characterized by decreased lung function, increased high-resolution computed tomography evidence of honeycombing (but not emphysema), as well as significant microscopic honeycombing and fibroblastic foci on pathology. The demographic and baseline characteristics of IPF patients and normal controls are presented in [Table I](#tI-ijmm-42-06-3256){ref-type="table"}. No significant differences in the patient number, age and gender between the normal and IPF groups were present.

A high-throughput microarray assay was used to identify circRNAs with abnormal expression in IPF. A total of 4,731 circRNA targets were detected using microarray probes in plasma samples from IPF patients and healthy individuals. The scatter plot in [Fig. 1A](#f1-ijmm-42-06-3256){ref-type="fig"} displays the variation in the circRNA expression ratio between the two groups. The heat map of circRNA expression in samples ofthe two groups in [Fig. 1B](#f1-ijmm-42-06-3256){ref-type="fig"} displays the regulation of several circRNA clusters. An upregulated cluster consisting of 38 circRNAs and a down-regulated cluster consisting of 29 circRNAs were detected in the patients (fold change, ≥1.5; P\<0.05). From the volcano plot in [Fig. 1C](#f1-ijmm-42-06-3256){ref-type="fig"}, differentially expressed circRNAs with statistical significance between IPF and control samples were identified. The distribution of circRNA in human chromosomes is illustrated in [Fig. 1D](#f1-ijmm-42-06-3256){ref-type="fig"}. A total of 21 and 18 of the most highly upregulated and downregulated circRNAs, respectively, according to their fold change, are listed in [Table II](#tII-ijmm-42-06-3256){ref-type="table"}.

Subsequently, six differentially expressed circRNA (hsa_circRNA_100906, hsa_circRNA_102100, hsa_circRNA_102348, hsa_circRNA_101225, hsa_circRNA_104780 and hsa_circRNA_101242) were selected for further validation and analysis due to their high fold-changes and low P-values. The expression levels were quantified via RT-qPCR with circRNA-specific divergent primers calibrated using standard curves with housekeeping genes as normalization standards. The RT-qPCR results validated the differential expression of these circRNAs by using 10 independent samples. The results indicated that, hsa_circRNA_100906, hsa_circRNA_102100 and hsa_circRNA_102348 were significantly upregulated, whereas hsa_circRNA_101225, hsa_circRNA_104780 and hsa_circRNA_101242 were significantly downregulated in the IPF vs. normal control samples ([Fig. 2](#f2-ijmm-42-06-3256){ref-type="fig"}). The changes in the expression of certain circRNAs identified from the overall array data were therefore in accordance with the results of theRT-qPCR measurements.

Genomic location of differentially expressed circRNAs in IPF disease
--------------------------------------------------------------------

circRNA is typically generated at the expense of canonical mRNA isoforms, thereby indicating its possible function as an important regulator of mRNA production ([@b22-ijmm-42-06-3256]). To predict the function of the circRNAs, their location in the human genome was first detected. Differentially expressed circRNA was typically derived from annotated exons (86.6%). Its splice sites typically span 1-11 exons and overlap the coding exon. Only small fractions of circRNA originated from introns or were aligned antisense regionsto known transcripts ([Fig. 3A](#f3-ijmm-42-06-3256){ref-type="fig"}).

Several differentially expressed circRNAs originated from known protein-coding genes with pivotal roles in fibrosis \[e.g. zinc-finger-DHHC-type with 4 (ZDHHC4)\]. Kyoto Encyclopaedia of Genes and Genomes (KEGG) analysis revealed that genes that produced dysregulated circRNAs were involved in the pathways of cell cycle, adherens junctions, ubiquitin-mediated proteolysis, and RNA transport and degradation ([Fig. 3B and C](#f3-ijmm-42-06-3256){ref-type="fig"}).

As presented in [Fig. 3D-I](#f3-ijmm-42-06-3256){ref-type="fig"}, the tested circRNAs all belonged to exons. In addition, exonic circRNAs may result from spliceosomal action, e.g. the exon structure of the human ankyrin repeat domain 42 locus, encompassing a 797-nt region that includes exons 3-8.

Predicted ceRNA network of circRNAs/miRNAs/mRNAs in IPF
-------------------------------------------------------

A considerable number of studies have reported that circRNAs act as 'miRNA sponges' to regulate gene expression. The present study evaluated the biological role of differentially expressed circRNAs by drawing and analysing an miRNA-mediated regulatory network. The number of predicted miRNA binding sites for all miRNAs (deposited in miR Base version 19) was determined. Interactions between circRNAs and miRNAs were theoretically predicted according to their conserved seed-matching sequences. The analysis revealed that all 67 of the differentially expressed circRNAs contained response elements for their respective target miRNAs. The top five miRNAs for each 67 circRNAs were displayed as a network delineated using Cytoscape software (version 3.1.0; [cytoscape.org/](http://cytoscape.org/)) ([Fig. 4A](#f4-ijmm-42-06-3256){ref-type="fig"}). A sub-network displaying 10 circRNAs and their target miRNAs is displayed in [Fig. 4B](#f4-ijmm-42-06-3256){ref-type="fig"}. Numerous associated miRNAs have pivotal roles in the progression of fibrotic disease (including miR-326, -361-5p, -338-3p, -9-5p, -136-5p, -145-5p, -224-5p and -877-3p). On the basis of the number of binding sites and target mRNAs, miR-330-5p/miR-324-5p, miR-532-5p, miR-630, miR-326, miR-650 and miR-338-3p/miR-21-3p were selected as potential miRNA targets for the six selected circRNAs (hsa_circRNA_100906, hsa_circRNA_102100, hsa_circRNA_102348, hsa_circRNA_101225, hsa_circRNA_104780 and hsa_circRNA_101242, respectively). The sequence analysis of the miRNA response elements for the six selected differentially expressed circRNAs and their potential complementary binding miRNAs is displayed in [Fig. 5](#f5-ijmm-42-06-3256){ref-type="fig"}. For instance, it was revealed that in hsa_circRNA_100906, the 154 to 159th and the 611 to 616th nucleotides starting from the 5′ terminus were completely complementary to the miR-324-5p seed region in the 8mer or 7mer-m8 binding mode.

Subsequently, circRNA_100906/miR-324-5p and circRNA_102348/miR-630 were selected to confirm the predicted interaction between circRNA and miRNA by lucif-erase reporter assays. The expression levels of miR-324-5p and miR-630 were significantly downregulated in IPF patients conversely to those of their associated circRNAs ([Fig. 6A and B](#f6-ijmm-42-06-3256){ref-type="fig"}). The luciferase intensity decreased by \>50% with the co-transfection of luciferase reporters containing the circRNA_100906 or circRNA_102348 full length sequence and mimics of miR-324-5p or miR-630, respectively. To confirm the direct interaction, the miRNA response elements (MREs) in the luciferase reporter were mutated. Co-transfection of miRNA mimics and luciferase reporter vector with the mutated sequence did not considerably affect the luciferase activity ([Fig. 6C-F](#f6-ijmm-42-06-3256){ref-type="fig"}).

miR-330-5p/miR-324-5p, miR-532-5p, miR-630, miR-326, miR-650 and miR-338-3p/miR-21-3p were predicted as target genes and the regulatory network of circRNAs/miRNAs/mRNAs is presented in [Fig. 7A](#f7-ijmm-42-06-3256){ref-type="fig"}. Numerous fibrosis-associated genes \[e.g. SMAD3, ECM protein 1 (ECM1), vimentin, suppressor of cytokine signalling 1 (SOCS1), rho-associated kinase (ROCK) 1, matrix metalloproteinase (MMP1), integrin subunit β like 1 (ITGBL1), ADAM metallopeptidase domain 17 and hypoxia-inducible factor 1 subunit α(HIF1A) inhibitor\] may be targeted by the previously mentioned miRNAs. The circRNA/miRNA regulatory networks act on target genes significantly involved in transforming growth factor (TGF)-β1, HIF-1, Wnt, Janus kinase (JAK), ROCK, vascular endothelial growth factor, mitogen-activated protein kinase, Hedgehog and nuclear factor κB signalling pathways, which are associated with cell proliferation, migration and collagen synthesis ([Fig. 7B](#f7-ijmm-42-06-3256){ref-type="fig"}). For instance, circRNA_100906 may trigger the upregulation of SOCS1, ROCK1, SP1, nemo-like kinase, MMP1, bromodomain containing 2, ECM1, ITGBL1, phosphoinositide-3-kinase regulatory subunit 3 and fibroblast growth factor receptor 2 by sequestering miR-324-5p and miR-330-5p in the network. The ceRNA network and associated pathway components may be novel clinical markers and therapeutic targets for IPF.

Discussion
==========

circRNAs are regarded as novel clinical diagnostic, prognostic and therapeutic biomarkers that may provide novel approaches for the treatment of diseases ([@b23-ijmm-42-06-3256]). For instance, the expression of circular ANRIL is correlated with the risk for atherosclerotic vascular disease ([@b24-ijmm-42-06-3256]). However, whether circRNAs have a role in IPF has remained elusive. In the present study, circRNA expression profiling was performed in IPF patients and 67 aberrantly expressed circRNAs were identified. Furthermore, it was unveiled that certain circRNAs (hsa_circRNA_100906, hsa_circRNA_102100 and hsa_circRNA_102348) were upregulated, while others (hsa_circRNA_101225, hsa_circRNA_104780 and hsa_circRNA_101242) were downregulated in IPF.

circRNA originates from exons, introns or is aligned with antisense regions to known transcripts, intergenic sequences or unannotated regions of the genome ([@b25-ijmm-42-06-3256]). Linear splicing and circRNA production compete against each other for splicing sites and assign a regulated function to circRNA in their hosted gene ([@b26-ijmm-42-06-3256]). Chao *et al* ([@b27-ijmm-42-06-3256]) reported that circRNA originating from the mouse formin (Fmn) gene functioned as an 'mRNA trap' by leaving a non-coding linear transcript, thereby reducing the expression levels of the Fmn protein. circRNA to eukaryotic translation initiation factor 3 subunit J and poly(A) binding protein interacting protein 2 are predominantly localized in the nucleus, interacting with U1 small nuclear ribonucleoproteins and enhancing the transcription of their parental genes in a cisacting manner ([@b28-ijmm-42-06-3256]). In the present study, numerous parental genes of differentially expressed circRNAs associated with the biological process of fibrosis were identified. Yang *et al*([@b29-ijmm-42-06-3256]) reported that ZDHHC4, which causes a significant downregulation of circRNAhsa_circ_104310, is a significant methylation marker to regulate the expression of large groups of genes in a trans-acting manner in IPF. André *et al*([@b30-ijmm-42-06-3256]) demonstrated that BRCA1-associated RING domain 1, the host gene of hsa_circRNA_102910, regulates lung epithelial cell damage and fibroblast proliferation by acting as a mediator of hypoxia and TGF-β may be a novel target for IPF treatment. hsa_circRNA_102348 is spliced from the elongator acetyltransferase complex subunit 2 gene, which encodes a general binding partner or chaperone for the activation and nuclear translocation of signal transducer and activator of transcription (STAT)3 ([@b31-ijmm-42-06-3256]) and may regulate the JAK/STAT signalling pathway. hsa_circRNA_102100 and 102101 align with the gene cell division cycle (CDC)27, which encodes a core component of the anaphase-promoting complex/cyclosome. Furthermore, aberrant expression of CDC27 may result in chromosomal aneuploidy integrity and improper cell cycle progression, which may have roles in cell proliferation in IPF ([@b32-ijmm-42-06-3256]). The parental gene of hsa_circRNA_101225 encodes a zinc finger MYM type 2, which apparently binds specifically to fibroblast growth factor receptor-1 or proteins with added small ubiquitin-like modifiers, including histone deacetylase 1 ([@b33-ijmm-42-06-3256]). KEGG analysis supported the concept of target genes that may regulate crucial biological processes during the development of IPF.

The highly complex regulator y network of circRNA/miRNA/mRNA represents another important layer of epigenetic control over gene expression in health and disease, involving a variety of cellular processes, including the cell cycle, apoptosis and adherens junctions ([@b34-ijmm-42-06-3256],[@b35-ijmm-42-06-3256]). At present, sponging activity is the major function of certain circRNAs. A 1.2-kb single-exon circRNA produced from the mammalian sex determination gene may function as a miR-138 sponge for 16 target sites ([@b36-ijmm-42-06-3256]). The circRNA/miRNA interaction analysis of the present study indicated that abnormally expressed circRNAs in IPF patients possess abundant miRNA target sites that have important roles in fibrotic disease. Zhang *et al* ([@b37-ijmm-42-06-3256]) reported that the miR-338-5p/lysophosphatidic acid receptor 1 axis may be regarded as a target of tectorigenin in bleomycin-induced lung fibrosis. In the present study, miR-338-5p was matched with hsa_circRNA_102101 and hsa_circRNA_102100, which originate from the same coding gene (CDC27). hsa_circRNA_101996 possessed MREs for miR-9 and -145, which regulated fibrosis by targeting platelet-derived growth factor receptor β/extracellular signal-regulated kinase signalling or the TGF-β receptor 2/SMAD3/TGF-β pathway ([@b38-ijmm-42-06-3256],[@b39-ijmm-42-06-3256]).

miRNAs including miR-324-5p, miR-330-5p, miR-532-5p, miR-630, miR-650, miR-21-3p and miR-326 reportedly participate in cell proliferation, apoptosis, migration, epithelial-mesenchymal transition (EMT), and cytoskeleton remodelling regarding as tumour markers ([@b40-ijmm-42-06-3256],[@b41-ijmm-42-06-3256]). However, limited information is available regarding their role in fibrotic disease. Pulmonary fibrosis is a neoproliferative disorder of the lung that exhibits several cancer-like pathogenic features, including abnormal activation, uncontrolled proliferation, resistance to apoptosis and high migration rates of myofibroblasts. These miRNAs were perfectly matched with the six circRNAs selected in the present study. MMP1, Snai2 and vimentin, which are the predicted target genes of miR-330-5p, 532-5p and 630, respectively, are mostly accepted as biomarkers for fibrosis. Early growth response 4, which contains binding sites for miR-326, reportedly counteracts autocrine TGF-β signalling and abolishes myofibroblast function ([@b42-ijmm-42-06-3256]). As a co-receptor for Wnt, low-density lipoprotein receptor related protein 5 and -6 are predicted targets of miR-532-5p, transmitting the canonical Wnt/β-catenin signalling and appearing independently associated with fibrotic disease progression ([@b43-ijmm-42-06-3256]). KEGG analysis further demonstrated the involvement of the target genes in fibrosis-associated signalling pathways.

circRNA_000203 is regarded as a ceRNA of collagen type I alpha 2 chain and connective tissue growth factor by interacting with miR-26b-5p in cardiac fibrosis ([@b44-ijmm-42-06-3256]). Furthermore, Zhou and Yu ([@b45-ijmm-42-06-3256]) reported that the profibrotic function of circRNA_010567 is partly mediated by the miR-141/TGF-β1 pathway. However, differential expression of the two circRNAs and the associated miRNAs was not observed in the present study. circRNA_101242, which harbours two binding sites for miR-21-3p, has been reported to be abnormally expressed in gastric cancer ([@b46-ijmm-42-06-3256]). In the present study, circRNA_101242 was also verified to be downregulated, whereas miR-21-3p was significantly upregulated in IPF. The direct binding and target mRNA require verification in further studies. A previous study reported that circRNA_100269 prevents gastric cancer proliferation by sponging miR-630 ([@b47-ijmm-42-06-3256]). However, in the present study, no evident change of circRNA_100269 was noted, whereas miR-630 was significantly downregulated in IPF patients. In addition, circRNA_102348, which harbours two MREs for miR-630, was upregulated and demonstrated to directly interact with miR-630. Previous studies have only identified a small number of circRNAs or ceRNAs with multiple binding sites for a particular miRNA; most circRNAs or ceRNAs were identified to contain only one or two miRNA binding sites ([@b48-ijmm-42-06-3256]). The predicted number of miRNA binding sites in differentially expressed circRNAs in the present study was three at the most as determined by Arraystar's prediction software. Furthermore, the interaction of circRNA_100906/miR-324-5p was identified in the present study. As a predicted target gene of miR-630, E1A binding protein p300was identified as a co-activator of HIF1A, which is responsible for lung fibrosis ([@b49-ijmm-42-06-3256]). Li *et al* ([@b50-ijmm-42-06-3256]) reported that the H19/miR-630/enhancer of zeste homolog 2(EZH2) signalling pathway has a considerable role in nasopharyngeal carcinoma metastasis. The activation of ROCK1 and -2, which are targeted by miR-324-5p according to the present analysis, is involved in actin filament assembly, actomyosin contraction, cell adhesion and motility, proliferation and apoptosis, and the remodelling of the ECM in lung fibrosis ([@b51-ijmm-42-06-3256]). miR-324-5p suppresses ECM degradation in hepatocellular carcinoma by post-transcriptionally downregulating ETS proto-oncogene 1, transcription factor and SP1 ([@b52-ijmm-42-06-3256]). Furthermore, ITGBL1, the predicted target gene of miR-324-5p, wasidentified to be significantly overexpressed in the lung tissue of bleomycin-injured mice and TGF-β1-treated cells, which inhibited EMT, myofibroblast migration and collagen synthesis (data not shown). The direct target genes of miR-630 and miR-324-5p in IPF will be further explored in future studies by our group.

In conclusion, the present study indicated that dysregulated circRNAs function as important regulators for pro- or anti-fibrotic signalling pathways in IPF by sequestering miRNAs or regulating their host genes. The important roles of circRNAs in IPF will be considered for further studies in our group. Ongoing efforts will be made to provide additional fundamental information for improving the understanding of the regulatory mechanisms in IPF and to provide novel approaches for the diagnosis, treatment and prevention of the disease.
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![circRNA expression profile in IPF patients. (A) Variations (or reproducibility) of circRNA expression between the experiment and control groups were visualized in a scatter plot. The values on the X- and Y-axis are the normalized signal values of the samples (log~2~ scaled) or the averaged normalized signal values of groups of samples (log~2~ scaled). The green lines represent the fold change of 1.5. The circRNAs above the top green line and below the bottom green line indicate circRNAs with a fold change of \>1.5 between the two compared samples. (B) Hierarchical clustering reveals the distinguishable circRNA expression profiling between IPF patients and normal human samples. Each column represents a sample and each row represents a circRNA. High or low relative expression is displayed as a red or green strip, respectively. Each group contains three different samples. (C) Volcano plots are useful tools for visualizing differential expression between two different conditions. The vertical lines correspond to a 1.5-fold up- and downregulation, and the horizontal line represents a P-value of 0.05. The red dots in the plot represent the differentially expressed circRNA with statistical significance. (D) Distribution of differentially expressed circRNAs in human chromosomes. Ctrl, control; IPF, idiopathic pulmonary fibrosis; circRNA, circular RNA; NC, normal control; hsa, *Homo sapiens*.](IJMM-42-06-3256-g00){#f1-ijmm-42-06-3256}

![Validation of the differential expression of circRNAs in IPF and normal control samples. The expression levels of circRNAs were detected usingreverse-transcription quantitative polymerase chain reaction. Gene expression was quantified using the ΔCt method with normalization to GAPDH expression levels. An higher ΔCt value indicates lower expression. Values are expressed as the mean ± standard deviation (n=10). ^\*^P\<0.05, ^\*\*^P\<0.01 or ^\*\*\*^P\<0.001 vs. the NC determined via unpaired Student's t-tests. IPF, idiopathic pulmonary fibrosis; circRNA, circular RNA; NC, normal control.](IJMM-42-06-3256-g01){#f2-ijmm-42-06-3256}

![Correlation of differential expression of circRNAs with their host genes. (A) Bar graph presenting the circRNA category. (B and C) Results of a Kyoto Encyclopedia of Genes and Genomes pathway analysis displaying the participant pathways of host genes. (D-I) Designated orientations and exon structure of detected six circRNA. For example, has_circRNA_104780 is formed when the 5′ splice site at the end of exon 4 is joined to the 3′ splice site at the beginning of exon 2 (purple). circRNA, circular RNA; Chr, chromosome; Sig, significantly enriched, UTR, untranslated region; hsa, *Homo sapiens.*ELP2, elongator acetyltransferase complex subunit 2; GRHPR, glyoxylate and hydroxypyruvate reductase; ANKRD42, ankyrin repeat domain 42; ZMYM2, zinc finger MYM-type containing 2; CDC27, cell division cycle 27; PAN3, poly(A) specific ribonuclease subunit PAN3.](IJMM-42-06-3256-g02){#f3-ijmm-42-06-3256}

![Interaction network of circRNAs and miRNAs. (A) circRNA-miRNA interaction network consisting of 38 upregulated circRNAs, 29 downregu-lated circRNAs and their target miRNAs. They were connected by 333 edges based on seed sequence pairing interactions. (B) Interaction of 10 circRNAs (including 6 verified circRNAs: hsa_circRNA_100906, hsa_circRNA_102100, hsa_circRNA_102348, hsa_circRNA_101225, hsa_circRNA_104780 and hsa_circRNA_101242; and 4 circRNAs with high expression and predicted binding, which serves an important role in lung fibrosis) and their target miRNAs presented in a magnified network. Red and green nodes represent upregulated and downregulated circRNAs, respectively. Purple nodes indicate miRNAs. miR/miRNA, microRNA; circRNA, circular RNA; hsa, *Homo sapiens.*](IJMM-42-06-3256-g03){#f4-ijmm-42-06-3256}

![Detailed annotation for circRNA/miRNA interaction based on TargetScan and miRanda. The '2D Structure' column presents the sequences of circRNA and miRNA. The 'Local AU' column displays 30 nucleotides upstream and downstream of the seed sequence. The 'Position' column indicates the probable position of the miRNA response element on the circRNA. (A and B) Interaction between hsa_circRNA_101242 and hsa_miR-21-3p or hsa_miR-338-3p, respectively. (C and D) Interaction between hsa_circRNA_100906 and hsa_miR-330-5p or hsa_miR-324-5p, respectively. (E-H) Display of the interaction of (E) hsa_circRNA_101225 and hsa_miR-326, (F) hsa_circRNA_102348 and hsa_miR-630, (G) hsa_circRNA_102100 and hsa_miR-532-5p and (H) hsa_circRNA_104780 and hsa_miR-650. miR/miRNA, microRNA; circRNA, circular RNA; UTR, untranslated region; hsa, *Homo sapiens.*](IJMM-42-06-3256-g04){#f5-ijmm-42-06-3256}

![Direct interaction between circRNA and miRNA. (A and B) Expression levels of miR-630 and miR-324-5p in IPF patients. ΔCt values were determined to quantify gene expression. Higher ΔCt value indicates lower expression. *C. elegans* miRNA 39-3p was used as a normalization control. Values are expressed as the mean ± standard deviation (n=10). ^\*\*^P\<0.01 vs. the NC group measured via unpaired Student's t-tests. (C) Wild-type and mutated miR-324-5p binding site on hsa_circRNA_100906. (D) hsa_circRNA_102348 sequences containing wild-type or mutated miR-630 binding sites. (E and F) Dual-luciferase reporter assay demonstrated direct binding or miR-324-5p and miR-630 with circRNA-100906 and circRNA-102348, respectively. Values are expressed as the mean ± standard deviation. ^\*\*\*^P\<0.001; ^\#\#\#^P\<0.001 measured via analysis of variance and Student-Newman-Keuls test. miR/miRNA, microRNA; IPF, idiopathic pulmonary fibrosis; circRNA, circular RNA; NC, normal control; WT, wild-type; MT, mutated type; Luc, luciferase; R, *Renilla*.](IJMM-42-06-3256-g05){#f6-ijmm-42-06-3256}

![Prediction ofcompeting endogenous RNA network of circRNAs/miRNAs/mRNAs. (A) Bioinformatics prediction of the circRNA/miRNA/mRNA network. Red represents circRNA, green represents mRNA and blue represents miRNA. (B) Kyoto Encyclopedia of Genes and Genomes analysis of pathways enriched by the targeted mRNAs. miR/miRNA, microRNA; circRNA, circular RNA. JAK, Janus kinase; STAT, signal transducer and activator of transcription; PI3K, phosphoinositide-3 kinase; HIF, hypoxia-inducible factor; TGF, transforming growth factor; VEGF, vascular endothelial growth factor; MAPK, mitogen-activated protein kinase.](IJMM-42-06-3256-g06){#f7-ijmm-42-06-3256}

###### 

Baseline characteristics and physiology of IPF patients and healthy individuals.

  --------------------------------------------------------------------------------------------------
  Characteristic              Controls\   IPF patients\
                              (n=10)      (n=10)
  --------------------------- ----------- ----------------------------------------------------------
  Age (years)                 67.5±8.7    67.2±9.6

  Gender (male/female)        6/4         6/4

  FVC (% of predicted)        88.9±10.2   59.6±9.2[a](#tfn1-ijmm-42-06-3256){ref-type="table-fn"}

  FEV1/FVC (% of predicted)   87.6±4.3    85.5±2.4

  TLC (% of predicted)        88.1±13.2   62.5±10.7[a](#tfn1-ijmm-42-06-3256){ref-type="table-fn"}

  DLCO (% of predicted)       87.8±4.6    53.3±10.6[a](#tfn1-ijmm-42-06-3256){ref-type="table-fn"}

  PaO~2~ (mmHg)               86.1±2.7    66.3±6.4[a](#tfn1-ijmm-42-06-3256){ref-type="table-fn"}

  PaCO~2~ (mmHg)              39.7±3.4    35.6±2.7

  Smoking history (%)         0           0
  --------------------------------------------------------------------------------------------------

P\<0.01 vs. the normal group determined via unpaired Student's t-tests. Values are expressed as the mean ± standard deviation. Smoking history denotes subjects with \>5 pack-years of cigarette smoking. FVC, forced vital capacity; FEV1/FVC, ratio of forced expiratory volume in the first second to forced vital capacity; TLC, total lung capacity; DLCO, diffusing capacity for carbon monoxide; IPF, idiopathic pulmonary fibrosis.

###### 

Most differentially expressed circRNA ranked by FC vs. NC group in microarray data.

  circRNA              P-value       FC (abs)    Change vs. NC    Alias              circRNA_type   Gene symbol
  -------------------- ------------- ----------- ---------------- ------------------ -------------- -------------
  hsa_circRNA_100906   0.00028136    1.8654768   Upregulation     hsa_circ_0023858   Exonic         ANKRD42
  hsa_circRNA_102380   0.000400941   1.5656011   Upregulation     hsa_circ_0047841   Exonic         LIG3
  hsa_circRNA_102913   0.000949382   1.5911579   Upregulation     hsa_circ_0058058   Exonic         ATIC
  hsa_circRNA_100705   0.001874312   2.4096969   Upregulation     hsa_circ_0008898   Exonic         OAT
  hsa_circRNA_100759   0.002180791   2.4327399   Upregulation     hsa_circ_0004099   Exonic         DENND5A
  hsa_circRNA_102100   0.006302884   2.6442716   Upregulation     hsa_circ_0044226   Exonic         CDC27
  hsa_circRNA_102348   0.010380106   2.1353111   Upregulation     hsa_circ_0007535   Exonic         ELP2
  hsa_circRNA_102101   0.033608302   2.1090716   Upregulation     hsa_circ_0044234   Exonic         CDC27
  hsa_circRNA_101550   0.043316607   2.3059601   Upregulation     hsa_circ_0035796   Exonic         HERC1
  hsa_circRNA_100657   0.011363912   1.8185249   Upregulation     hsa_circ_0006520   Exonic         MMS19
  hsa_circRNA_103712   0.02802823    1.8542931   Upregulation     hsa_circ_0007540   Exonic         TBCK
  hsa_circRNA_104211   0.030050202   1.8239174   Upregulation     hsa_circ_0007762   Exonic         STXBP5
  hsa_circRNA_104532   0.04568836    1.8495971   Upregulation     hsa_circ_0001772   Exonic         RBM33
  hsa_circRNA_102038   0.034423041   1.541653    Upregulation     hsa_circ_0043082   Exonic         LIG3
  hsa_circRNA_104840   0.013111444   1.5986307   Upregulation     hsa_circ_0002780   Exonic         CDC14B
  hsa_circRNA_101487   0.003102427   1.6784173   Upregulation     hsa_circ_0008926   Exonic         NUSAP1
  hsa_circRNA_103626   0.040907511   1.5692823   Upregulation     hsa_circ_0007308   Exonic         PDS5A
  hsa_circRNA_102771   0.049588502   1.5610834   Upregulation     hsa_circ_0055377   Exonic         CTNNA2
  hsa_circRNA_101691   0.009068437   1.6051068   Upregulation     hsa_circ_0007637   Exonic         CREBBP
  hsa_circRNA_100832   0.014303719   1.6414589   Upregulation     hsa_circ_0022378   Exonic         FADS1
  hsa_circRNA_101272   0.012972773   1.6474556   Upregulation     hsa_circ_0005783   Exonic         KLF12
  hsa_circRNA_101225   0.000635675   2.5487789   Downregulation   hsa_circ_0029633   Exonic         ZMYM2
  hsa_circRNA_101025   0.002349167   1.6468162   Downregulation   hsa_circ_0025633   Exonic         LRMP
  hsa_circRNA_104780   0.00453198    2.4221486   Downregulation   hsa_circ_0001861   Exonic         GRHPR
  hsa_circRNA_101004   0.006100264   1.9569623   Downregulation   hsa_circ_0000375   Exonic         IFFO1
  hsa_circRNA_102049   0.011284484   4.1574829   Downregulation   hsa_circ_0043278   Exonic         TADA2A
  hsa_circRNA_101192   0.020134914   2.2308587   Downregulation   hsa_circ_0005465   Exonic         CLIP1
  hsa_circRNA_102470   0.0264833     2.2000704   Downregulation   hsa_circ_0049888   Exonic         EPS15L1
  hsa_circRNA_000993   0.030740567   1.9544226   Downregulation   hsa_circ_0001887   Intragenic     STRBP
  hsa_circRNA_101242   0.03320098    1.9118807   Downregulation   hsa_circ_0029853   Exonic         PAN3
  hsa_circRNA_100477   0.005705005   1.6533506   Downregulation   hsa_circ_0016867   Exonic         COG2
  hsa_circRNA_100476   0.007246795   1.8857807   Downregulation   hsa_circ_0016863   Exonic         COG2
  hsa_circRNA_001166   0.006309977   1.9935227   Downregulation   hsa_circ_0001556   Intronic       ERGIC1
  hsa_circRNA_103225   0.009486195   1.8307713   Downregulation   hsa_circ_0063331   Exonic         DDX17
  hsa_circRNA_104310   0.016308893   1.7897346   Downregulation   hsa_circ_0079385   Exonic         ZDHHC4
  hsa_circRNA_000424   0.003435538   1.8528501   Downregulation   hsa_circ_0001549   Antisense      FABP6
  hsa_circRNA_103977   0.046667432   1.5710154   Downregulation   hsa_circ_0074362   Exonic         ARHGAP26
  hsa_circRNA_103178   0.029174857   1.6035583   Downregulation   hsa_circ_0062577   Exonic         CABIN1
  hsa_circRNA_102910   0.041706263   1.5010713   Downregulation   hsa_circ_0058051   Exonic         BARD1

Regarding the circRNA type, circRNA is classified into four categories: Exonic, intronic, antisense and intergenic. The P-value was calculated using anunpaired Student's t-test. FC (abs), absolutefold change; Alias, circRNA ID in the circ Base database (circbase.mdc-berlin.de); circRNA, circular RNA; NC, normal control; hsa, *Homo sapiens.*
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